EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Prenatal Screening and Diagnostic Considerations for 22q11.2 Microdeletions

Natalie Blagowidow iD, Beata Nowakowska, Erica Schindewolf, Francesca Romana Grati, Carolina Putotto iD, Jeroen Breckpot, Ann Swillen, Terrence Blaine Crowley iD, Joanne C Y Loo iD, Lauren A Lairson, Sólveig Óskarsdóttir iD, Erik Boot iD und 7 weitere

Genes · 06.01.2023 · 14 (1) · 160

DOI: 10.3390/genes14010160 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 06.01.2023. Verfasst von Natalie Blagowidow und 18 weiteren Autor:innen. Beteiligte Einrichtung: Harvey Institute for Human Genetics, Greater Baltimore Medical Center, Baltimore, MD 21204, USA. Hauptthemen laut MEDLINE: DiGeorge Syndrome, Heart Defects, Congenital, Fetal Diseases. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diagnosis of a chromosome 22q11.2 microdeletion and its associated deletion syndrome (22q11.2DS) is optimally made early. We reviewed the available literature to provide contemporary guidance and recommendations related to the prenatal period. Indications for prenatal diagnostic testing include a parent or child with the 22q11.2 microdeletion or suggestive prenatal screening results. Definitive diagnosis by genetic testing of chorionic villi or amniocytes using a chromosomal microarray will detect clinically relevant microdeletions. Screening options include noninvasive prenatal screening (NIPS) and imaging. The potential benefits and limitations of each screening method should be clearly conveyed. NIPS, a genetic option available from 10 weeks gestational age, has a 70–83% detection rate and a 40–50% PPV for most associated 22q11.2 microdeletions. Prenatal imaging, usually by ultrasound, can detect several physical features associated with 22q11.2DS. Findings vary, related to detection methods, gestational age, and relative specificity. Conotruncal cardiac anomalies are more strongly associated than skeletal, urinary tract, or other congenital anomalies such as thymic hypoplasia or cavum septi pellucidi dilatation. Among others, intrauterine growth restriction and polyhydramnios are additional associated, prenatally detectable signs. Preconception genetic counselling should be offered to males and females with 22q11.2DS, as there is a 50% risk of transmission in each pregnancy. A previous history of a de novo 22q11.2 microdeletion conveys a low risk of recurrence. Prenatal genetic counselling includes an offer of screening or diagnostic testing and discussion of results. The goal is to facilitate optimal perinatal care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DiGeorge SyndromeHeart Defects, CongenitalFetal DiseasesPregnancyMaleChildFemaleHumansPrenatal DiagnosisGenetic Testing

Stichwörter der Autor:innen

22q11.2 deletion syndromefetal cardiac anomalynoninvasive prenatal screeningpreimplantation genetic testingprenatal ultrasound

Autor:innen und Institutionen

  • Harvey Institute for Human Genetics, Greater Baltimore Medical Center, Baltimore, MD 21204, USA.
  • Cytogenetic Laboratory, Department of Medical Genetics, Institute of Mother and Child, Kasprzaka 17a, 01-211 Warsaw, Poland.
  • Center for Fetal Diagnosis and Treatment and the 22q and You Center, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
  • R&D Department, Menarini Biomarkers Singapore, Via Giuseppe di Vittorio 21/b3, 40013 Castel Maggiore, Italy.
  • Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome (Italy), Viale del Policlinico 155, 00161 Roma, Italy.
  • Center for Human Genetics, Herestraat 49, 3000 Leuven, Belgium.

ORCID-Profile: Natalie Blagowidow, Carolina Putotto, Terrence Blaine Crowley, Joanne C Y Loo, Sólveig Óskarsdóttir, Erik Boot, Anne S Bassett, Donna M McDonald-McGinn

Förderung

  • NICHD NIH HHS

Zitieren

APA

Blagowidow, N., Nowakowska, B., Schindewolf, E., Grati, F. R., Putotto, C., Breckpot, J., Swillen, A., Crowley, T. B., Loo, J. C. Y., Lairson, L. A., Óskarsdóttir, S., Boot, E., Garcia-Minaur, S., Cristina Digilio, M., Marino, B., Coleman, B., Moldenhauer, J. S., Bassett, A. S., & McDonald-McGinn, D. M. (2023). Prenatal Screening and Diagnostic Considerations for 22q11.2 Microdeletions. Genes, 14(1), 160. https://doi.org/10.3390/genes14010160

Vancouver

Blagowidow N, Nowakowska B, Schindewolf E, Grati FR, Putotto C, Breckpot J, et al. Prenatal Screening and Diagnostic Considerations for 22q11.2 Microdeletions. Genes. 2023;14(1):160. doi:10.3390/genes14010160

BibTeX
@article{Blagowidow2023,
  author = {Blagowidow, Natalie and Nowakowska, Beata and Schindewolf, Erica and Grati, Francesca Romana and Putotto, Carolina and Breckpot, Jeroen and Swillen, Ann and Crowley, Terrence Blaine and Loo, Joanne C Y and Lairson, Lauren A and Óskarsdóttir, Sólveig and Boot, Erik and Garcia-Minaur, Sixto and Cristina Digilio, Maria and Marino, Bruno and Coleman, Beverly and Moldenhauer, Julie S and Bassett, Anne S and McDonald-McGinn, Donna M},
  title = {Prenatal Screening and Diagnostic Considerations for 22q11.2 Microdeletions},
  journal = {Genes},
  year = {2023},
  volume = {14},
  number = {1},
  pages = {160},
  doi = {10.3390/genes14010160}
}
Kostenlos starten →